Chemotherapy, AdjuvantAntineoplastic Combined Chemotherapy ProtocolsAdjuvants, ImmunologicCombined Modality TherapyFreund's AdjuvantTreatment OutcomeAntineoplastic AgentsRadiotherapy, AdjuvantCisplatinCyclophosphamideBreast NeoplasmsDoxorubicinDisease-Free SurvivalNeoplasm StagingNeoadjuvant TherapySurvival AnalysisPrognosisAdjuvants, PharmaceuticSurvival RateNeoplasm Recurrence, LocalDrug Administration ScheduleMethotrexateEtoposideLung NeoplasmsPaclitaxelFollow-Up StudiesCarboplatinTaxoidsVinblastineTime FactorsAntimetabolites, AntineoplasticNeoplasmsInduction ChemotherapyAnthracyclinesDrug Resistance, NeoplasmDeoxycytidineOrganoplatinum CompoundsClinical Trials as TopicIfosfamideAdenocarcinomaRandomized Controlled Trials as TopicNeoplasm MetastasisTamoxifenAntineoplastic Agents, AlkylatingBleomycinProspective StudiesLymphatic MetastasisCarcinoma, Non-Small-Cell LungKaplan-Meier EstimateColorectal NeoplasmsSalvage TherapyAntineoplastic Agents, HormonalChemotherapy, Cancer, Regional PerfusionOvarian NeoplasmsRadiotherapyCytarabineTesticular NeoplasmsNeutropeniaTumor Markers, BiologicalDacarbazineAntineoplastic Agents, PhytogenicVomitingAluminum HydroxideRecurrenceTransplantation, AutologousNauseaAntibiotics, AntineoplasticBrain NeoplasmsBone NeoplasmsAntibodies, Monoclonal, HumanizedDose-Response Relationship, DrugLymphoma, Non-HodgkinLomustineTegafurHodgkin DiseaseLiver NeoplasmsMitomycinStomach NeoplasmsGranulocyte Colony-Stimulating FactorMultivariate AnalysisInfusions, IntravenousNeoplasms, Germ Cell and EmbryonalInsurance BenefitsRadiotherapy DosageCarmustineOsteosarcomaCamptothecinReceptors, EstrogenProportional Hazards ModelsDrug TherapyQuality of LifePlatinum CompoundsMastectomyReceptor, erbB-2Mice, Inbred BALB CDisease ProgressionAntibodies, MonoclonalCarcinomaCell Line, TumorPalliative Care